1）Maloney DG, et al. IDEC-C2B8 (rituximab)
anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade
non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
2）McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal
antibody therapy for relapsed indolent lymphoma-half of patients respond
to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
3）Hainsworth JD, et al. Rituximab monoclonal antibody
as initial therapy for patients with low-grade non-Hodgkin lymphoma.
Blood 2000;95:3052-6.
4）Colombat P, et al. Rituximab (anti-CD20 monoclonal
antibody) as single first-line therapy for patients with follicular
lymphoma with a low tumor burden: clinical and molecular evaluation.
Blood 2001;97:101-6.
5）Davis TA, et al. Rituximab anti-CD20 monoclonal antibody
therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
J Clin Oncol 2000;18:3135-43.
6）Winkler U, et al. Cytokine-release syndrome in patients
with B-cell chronic lymphocytic leukemia and high lymphocyte counts
after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Blood 1999;94:2217-24.
7）Czuczman MS, et al. Treatment of patients with low-grade
B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal
antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
8）Magni M, et al. Successful in vivo purging of
CD34-containing peripheral blood harvests in mantle cell lymphoma and
indolent lymphoma: evidence for a role of both chemo-therapy and rituximab
infusion. Blood 2000;96:864-9.
9）Coiffier B, et al. Mabthera (rituximab) plus CHOP is
superior to CHOP alone in elderly patients with diffuse large B-cell
lymphoma (DLCL):interim results of a randomized GELA trial. Blood 2000;96:223a.
10）Kaminski MS, et al. Radioimmunotherapy with iodine
131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:
updated results and long-term follow-up of the University of Michigan
experience. Blood 2000;96:1259-66.
11）Press OW, et al. A phase I/II trial of iodine-131-tositumomab
(anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation
for relapsed B-cell lymphomas. Blood 2000;96:2934-42.
12）Druker BJ, et al. Clinical efficacy and safety of
an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic
myelogenous leukemia. Blood 1999;94:368a.
13）Kantarjian H, et al. Phase II study of STI571, a
tyrosine kinase inhibitor, in patients with resistant or refractory
Philadelphia chromosome-positive chronic myeloid leukemia. Blood 2000;96:470a.
14）Thiesing JT, et al. Efficacy of STI671, an Abl tyrosine
kinase inhibitor, in conjunction with other antileukemic agents against
Bcr-Abl-positive cells. Blood 2000;96:3195-9.
15）Talpaz M, et al. A phase II study of STI 571 in adult
patients with Philadelphia chromosome positive chronic myeloid leukemia
in accelerated phase. Blood 2000;96:469a.
16）Singhal S, et al. Antitumor activity of thalidomide
in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
17）Hideshima T, et al. Thalidomide and its analogs overcome
drug resistance of human multiple myeloma cells to conventional therapy.
Blood 2000;96:2943-50.
18）Schreiber S, et al. Multiple myeloma with deletion
of chromosome 13q is characterized by increased bone marrow neovascularization.
Br J Haematol 2000;110:605-9.
19）Mangi M, Newland AC. Angiogenesis and angiogenic
mediators in hematological malignancies. Br J Haematol 2000;111:43-51.
20）Childs R, et al. Engraft kinetics after nonmyeloablative
allogeneic peripheral blood stem cell transplantation: Full donor T-cell
chimerism precedes alloimmune responses. Blood 1999;94:3234-41.
21）Barrett J, Childs R: Non-myeloablative stem cell
transplants. Br J Haematol 2000;111:6-17.
22）Carella AM, et al. Autografting followed by nonmyeloablative
immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic
stem-cell transplantation as treatment of resistant Hodgkin's disease
and non-Hodgkin's lymphoma. J Clin Oncol 2000;18:3918-24.